Focus: Azitra is a public-stage biotechnology company focused on microbiome-based skin treatments, headquartered in Branford, CT. The company operates as a pre-revenue biotech with minimal commercial traction and a research-intensive pipeline.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Azitra to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Azitra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Azitra's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Azitra (NYSE: AZTR) sets June 15 date to reconvene 2026 virtual annual meeting - Stock Titan
Azitra (NYSE: AZTR) sets June 15 date to reconvene 2026 virtual annual meeting Stock Titan
Proxy mailing delay pushes Azitra’s virtual shareholder meeting - Stock Titan
Proxy mailing delay pushes Azitra’s virtual shareholder meeting Stock Titan
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight - PR Newswire
Netherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight PR Newswire
Biotech testing new rash and wrinkle treatments posts Q1 loss, $10.1M cash - Stock Titan
Biotech testing new rash and wrinkle treatments posts Q1 loss, $10.1M cash Stock Titan
New U.S. patent covers trial therapy for a rare skin disease with no approved drugs - Stock Titan
New U.S. patent covers trial therapy for a rare skin disease with no approved drugs Stock Titan
Azitra's skin bacteria therapy cut water loss in pig skin tests - Stock Titan
Azitra's skin bacteria therapy cut water loss in pig skin tests Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo